Archives
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Many studies reporting on discoveries of DUBs
2020-01-16

Many studies reporting on discoveries of DUBs in the TGFβ and BMP pathways have relied on RNAi strategies to investigate loss-of-function impact. While RNAi strategies are useful tools, there are limitations ranging from limited knockdowns of targets to potential off-target effects. New and better t
-
The activity of chromenones bearing heteroaryl groups at the
2020-01-16

The activity of chromenones bearing heteroaryl groups at the 8-position is summarised in . Replacement of the 8-phenyl substituent of by a thiophen-2-yl group ( and ) did not improve DNA-PK inhibitory activity, although the 4-phenylthiophen-2-yl derivative (), together with the bithiophene analogue
-
In general the DNMT encompass three different structural reg
2020-01-16

In general, the DNMT encompass three different structural regions: N-terminal regulatory domain, C-terminal catalytic domain and a central linker region (). The N-terminal regulatory domain is particularly implicated in determining subcellular localization of the DNMT and in allocating unmethylated
-
In children only the genotype was
2020-01-16

In children, only the 6/7 genotype was associated with spina bifida, increasing the risk about 4 times relative to the DHFR 3/3 and 6/6 genotypes. However, the 95%CIs are broad and only few spina bifida patients have the DHFR 6/7 genotype. The effect of the 6/7 genotype on spina bifida risk is there
-
Recent pharmaceutical research in the
2020-01-16

Recent pharmaceutical research in the field of respiratory diseases has sought to make available new agents that specifically and selectively antagonize the actions of cysteinyl–leukotrienes. Such an effort has resulted in the development of two classes of drugs, effective in counteracting Cys-LTs p
-
These evidence prompted us to investigate the effectiveness
2020-01-16

These evidence prompted us to investigate the effectiveness of CT-133, a newly discovered, well-tolerated, selective and potent CRTH2 antagonist, as a treatment of ALI. CT-133 has shown a potential response in treating chronic obstructive pulmonary disease (COPD), allergic rhinitis and CH5138303 (G
-
CPH models reported usually as lists of
2020-01-16

CPH models, reported usually as lists of risk factors along with their parameters, are prevalent in medical literature. One such model is the CPH model created for the purpose of predicting the probability of one year survival of patients suffering from Pulmonary Arterial Hypertension [5]. The model
-
Importantly our in vivo data fit to
2020-01-15

Importantly, our in vivo data fit to the in vitro data, further confirming the synergistic effect of XJD and gefitinib on the inhibition of lung cancer and the regulation of SP1, HOTAIR, and EP4 calcium channel blockers levels. The doses of XJD used were based on our previous in vivo study (Zhao et
-
A recent study reports the expression of
2020-01-15

A recent study reports the expression of glutathione-dependent enzymes (GGT, GST-isoforms, gamma-glutamylcysteine synthetase, glutathione disulfide reductase and GSH peroxidase) in human primary PT Guanethidine Sulfate in four subsequent passages [33]. In this study, we present phase I and II activ
-
auz Downregulation of tumor suppressors is a major factor
2020-01-15

Downregulation of tumor suppressors is a major factor that leads to tumorigenesis. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN), a common tumor suppressor, the auz of which is often downregulated or even absent in the majority of human cancers, functions as a phosphatase to dephosp
-
br Materials and methods br Results br Discussion
2020-01-15

Materials and methods Results Discussion The first DGAT1 gene was described in the mouse in 1998 [28], and a few years later DGAT2 was identified from the oleaginous fungus Mortierella ramanniana[29]. Although both of them are known as the primary enzymes for de novo TAG biosynthesis, they
-
The only in vivo evidence for a role
2020-01-15

The only in vivo evidence for a role of DDR2 in fibrotic disease showed that DDR2 knockout mice exhibited exaggerated severity of chronic hepatic fibrosis. Although a previous in vitro study has demonstrated that DDR2 promotes lung fibroblast proliferation and migration, till now it remains unclear
-
Ozagrel br Materials and methods br Results br Discussion CD
2020-01-15

Materials and methods Results Discussion CDK and their regulatory cyclins form a family of heterodimeric kinases that are particularly important for regulation of Ozagrel progression and transcription in tumor cells. These kinases therefore constitute biomarkers of proliferation and attract
-
br Materials and methods br Results br Discussion This study
2020-01-15

Materials and methods Results Discussion This study is the first to our knowledge that describes upstream cis-elements and transcription factors that are important for Crm1 expression and that drive its high expression in cancer and transformed cells. Using deletion and mutation analysis we
-
Numerous small molecule CRF receptor antagonists
2020-01-15

Numerous small molecule CRF receptor antagonists have been reported in the literature. Some representative examples are shown in . In preclinical studies (DMP696), , was found to be efficacious in preclinical behavioral models for anxiety and depression. In an open label clinical trial with (R121
16135 records 904/1076 page Previous Next First page 上5页 901902903904905 下5页 Last page